Why is telopol more effective than other weight loss drugs? ——The scientific principle of GLP-1/GIP dual agonism
In the field of weight loss drugs, GLP-1 receptor agonists (such as semaglutide and liraglutide) have become mainstream, helping countless people successfully lose weight and improve metabolic health . However, the emergence of the latest generation of **GLP-1/GIP dual agonists , telopoietin ( Mounjaro/Zepbound ) ** , has brought weight loss effects to a new level.
Why is tepote more effective in weight loss? What are the advantages of its GLP-1/GIP dual agonist mechanism compared to traditional GLP-1 drugs? This article will analyze why tepote is currently the strongest FDA -approved weight loss drug from multiple aspects such as mechanism of action, clinical data, fat metabolism, and tolerance .
1. GLP-1/GIP dual agonist mechanism vs. traditional GLP-1 mechanism
1.1. Effects of GLP-1 receptor agonists (such as semaglutide)
GLP-1 (glucagon-like peptide -1 ) is an important hormone in the human body that regulates appetite and blood sugar metabolism . GLP-1 receptor agonists (such as semaglutide and liraglutide) mainly help weight loss in the following ways:
✔ Reduce appetite : It acts on the appetite center of the hypothalamus in the brain, reduces hunger, and makes people actively reduce the amount of food they eat.
✔ Delay gastric emptying : Allow food to stay in the stomach longer, increase satiety, and reduce the urge to eat.
✔ Promote insulin secretion and lower blood sugar : Helps with weight management in people with type 2 diabetes and metabolic abnormalities .
📌 limitation :
• It mainly relies on reducing calorie intake, and has limited effect on fat decomposition , resulting in slower weight loss in some patients.
• GLP-1 drugs have common strong gastrointestinal side effects, such as nausea, vomiting, and diarrhea, which affect tolerance.
1.2. GLP-1/GIP dual agonist mechanism of tepoxetine: why is the effect stronger?
Tipoline is the first weight loss drug that activates both GLP-1 and GIP receptors , and its effects are more comprehensive:
✔ GLP-1 effect (same as semaglutide): reduces appetite, delays gastric emptying, and lowers blood sugar.
✔ GIP function (unique advantage):
• Accelerate fat decomposition, improve energy metabolism , and allow the body to burn fat more efficiently.
• Enhances insulin sensitivity , lowers blood sugar and improves metabolism more effectively than GLP-1 monoagonists.
• Reduce the gastrointestinal side effects of GLP-1 drugs and improve tolerance .
📌 Why does GIP receptor agonism enhance weight loss?
1️Promote fat oxidation : GLP-1 drugs mainly reduce weight by reducing food intake, while GIP can directly promote fat decomposition and speed up fat burning in the body.
2️Reduce muscle loss : Traditional GLP-1 drugs may cause some muscle loss while reducing fat, while the metabolic regulation effect of GIP can help maintain muscle mass .
3️Reduce nausea and vomiting and improve tolerance : One of the side effects of GLP-1 drugs is gastrointestinal discomfort, and GIP receptor stimulant can alleviate these side effects and improve patient long-term compliance .
💡 Conclusion: GLP-1 drugs reduce body weight mainly by reducing appetite, while GLP-1/GIP dual agonists not only reduce appetite but also accelerate fat burning, making weight loss faster and more stable.
2. Comparison of clinical data: telpotide vs. semaglutide
Several clinical trials (such as SURMOUNT-1 and STEP-1 ) have compared the weight loss effects of telpotide and semaglutide , with the following results:
|
Research |
Tipocapeptide ( GLP-1/GIP dual agonist) |
Semaglutide ( GLP-1 monoagonist) |
|
Weight loss (average) |
22.5% weight loss after 72 weeks ( SURMOUNT-1 study) |
16.9% weight loss after 68 weeks ( STEP-1 study) |
|
Proportion of people with weight loss ≥ 20% |
57% |
36% |
|
Maximum weight loss |
Up to 27% |
Up to 18% |
📌 Key findings :
✔ The average weight loss of tebuconazole in the same period was 5.6% higher than that of semaglutide , and the long-term weight loss effect was stronger.
✔ 57% of patients lost ≥20% of their body weight , compared with only 36% of patients taking semaglutide.
💡 Conclusion: The GLP-1/GIP effect of tepoxetine can enable patients to lose weight faster and to a greater extent, and it is the most effective GLP-1 drug on the market.
3. Telbutide vs. other weight loss drugs: effect comparison
|
drug |
Mechanism of action |
Weight loss ( 1 year) |
side effect |
|
Telportide |
GLP-1 + GIP dual agonist |
22.5% |
Mild gastrointestinal discomfort |
|
Semaglutide |
GLP-1 single agonist |
16.9% |
Nausea and vomiting are more obvious |
|
Orlistat |
Inhibit fat absorption |
7-10% |
Diarrhea, oily stools |
|
Naltrexone - Bupropion |
Central nervous system appetite suppressant |
5-10% |
May affect sleep and mood |
📌 Conclusion: Telpotide is superior to other weight loss drugs in terms of weight loss effect, and its side effects are milder than semaglutide.
4. Conclusion: Why is tebuconazole the most powerful weight loss drug currently?
📌 Summary of core advantages
✔ GLP-1 + GIP dual stimulation : not only reduces appetite, but also accelerates fat burning , making weight loss faster and more stable.
✔ The strongest weight loss effect : the average weight loss within 72 weeks was 22.5% , far exceeding semaglutide ( 16.9% ).
✔ Reduce side effects and improve tolerance : GIP can reduce nausea and vomiting and improve patient compliance .
✔ More comprehensive metabolic improvement : not only reduces weight, but also lowers blood sugar, reduces insulin resistance, and improves cardiovascular health .
💡 Final conclusion: The GLP-1/GIP dual agonist mechanism of tebuconazole makes it the strongest FDA -approved weight loss drug on the market. It is more effective and gentler than traditional GLP-1 drugs and is the most worthwhile investment option for weight loss.
🛒Mounjaro 2.5mg *2 sticks / box *2
--------------------------------
Welcome to add customer service to get new customer discount
Customer Service 1 ： AobMedical
Customer Service 2 ： Aob202404
Kent : +1 6462071346
Asakusa makeup: +81 8070566715
